Fig. 1From: Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trialTime course of FMD in patients administered evolocumab plus empagliflozin (circle) or empagliflozin (square). Graph A plots resting FMD curves in both study arms during the pre-randomization phase. Graphs B and C show resting FMD curves for the empagliflozin and evolocumab plus empagliflozin arms, respectively, at baseline, 8Â weeks, and after 16Â weeks of treatmentBack to article page